Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Altamira Therapeutics provides update on Bentrio program » 07:55
09/27/21
09/27
07:55
09/27/21
07:55
CYTO

Cytogen

$2.35 /

+0.03 (+1.29%)

Altamira Therapeutics…

Altamira Therapeutics provided a business update on Bentrio , its nasal spray for protection against airborne viruses and allergens. Bentrio was launched first in Germany under CE mark in late July and subsequently also in Austria. During the initial launch stage, the nasal spray product has been marketed solely through leading online pharmacies, supported by digital campaigns combined with classic instruments. The Bentrio.com website is currently receiving approximately 2,500 visitors per day in Germany, and traffic is continuing to grow. Promotional activities are being progressively expanded to further European countries. In the next phase of the European launch of Bentrio starting in Q4 , the Company will also target traditional 'brick-and-mortar' pharmacy stores. With the goal of accessing the large potential U.S. market for Bentrio the Company has recently submitted a 510 premarket notification to the FDA. The claimed use for Bentrio is the treatment of hay fever and allergy sufferers by promoting alleviation of mild allergic symptoms triggered by the inhalation of various airborne allergens. These include indoor and outdoor environmental pollens, house dust, animal hair and dust mites. Once cleared, the Company anticipates partnering Bentrio for the U.S. market rather than commercializing it there on its own. Altamira also sees significant business development opportunities for Bentrio in international markets. In that regard, the Company recently executed letters of understanding with distributors in two key Southeast Asian countries, with national registrations being initiated. Based on a growing number of leads and strong interest in the product, Altamira expects to expand the geographic footprint for Bentrio rapidly through agreements with additional distributors.

ShowHide Related Items >><<
CYTO Cytogen
$2.35 /

+0.03 (+1.29%)

Conference/Events
Cytogen to host conference call » 07:55
09/27/21
09/27
07:55
09/27/21
07:55
CYTO

Cytogen

$2.35 /

+0.03 (+1.29%)

Management provides a…

Management provides a business update on the Bentrio program on a conference call to be held on September 27 at 8 am. Webcast Link

ShowHide Related Items >><<
CYTO Cytogen
$2.35 /

+0.03 (+1.29%)

Conference/Events
Cytogen to host conference call » 04:55
09/27/21
09/27
04:55
09/27/21
04:55
CYTO

Cytogen

$2.35 /

+0.03 (+1.29%)

Management provides a…

Management provides a business update on the Bentrio program on a conference call to be held on September 27 at 8 am. Webcast Link

ShowHide Related Items >><<
CYTO Cytogen
$2.35 /

+0.03 (+1.29%)

Conference/Events
Cytogen to host conference call » 16:57
09/25/21
09/25
16:57
09/25/21
16:57
CYTO

Cytogen

$2.35 /

+0.03 (+1.29%)

Management provides a…

Management provides a business update on the Bentrio program on a conference call to be held on September 27 at 8 am. Webcast Link

ShowHide Related Items >><<
CYTO Cytogen
$2.35 /

+0.03 (+1.29%)

Over a month ago
Options
Four new option listings and four option delistings on July 26th » 08:30
07/26/21
07/26
08:30
07/26/21
08:30
CYTO

Cytogen

$3.04 /

-0.04 (-1.30%)

, LCID

Lucid Group

/

+

, MVST

Microvast

/

+

, RTPZ

Reinvent Technology Partners Z

$9.99 /

+0.02 (+0.20%)

, CCIV

Churchill Capital Corp IV

$24.22 /

+1.27 (+5.53%)

, EARS

Auris Medical

/

+

, HOME

At Home Group

$36.99 /

+ (+0.00%)

, THCB

Tuscan Holdings Corp.

$9.99 /

-0.21 (-2.06%)

New option listings for…

New option listings for July 26th include Altamira Therapeutics Ltd (CYTO), Lucid Group Inc (Class A Stock) (LCID), Microvast Holdings Inc (MVST), and Reinvent Technology Partners Z (Class A Stock) (RTPZ). Option delistings effective July 26th include Churchill Capital Corp IV (Class A Stock) (CCIV), Auris Medical Holding AG (EARS), At Home Group Inc (HOME), and Tuscan Holdings Corporation (THCB).

ShowHide Related Items >><<
THCB Tuscan Holdings Corp.
$9.99 /

-0.21 (-2.06%)

RTPZ Reinvent Technology Partners Z
$9.99 /

+0.02 (+0.20%)

MVST Microvast
/

+

LCID Lucid Group
/

+

HOME At Home Group
$36.99 /

+ (+0.00%)

EARS Auris Medical
/

+

CCIV Churchill Capital Corp IV
$24.22 /

+1.27 (+5.53%)

CYTO Cytogen
$3.04 /

-0.04 (-1.30%)

LCID Lucid Group
/

+

MVST Microvast
/

+

RTPZ Reinvent Technology Partners Z
$9.99 /

+0.02 (+0.20%)

CCIV Churchill Capital Corp IV
$24.22 /

+1.27 (+5.53%)

05/10/21 Wedbush
Tesla demand looks robust so far in Q2 despite rising competition, says Wedbush
02/23/21 Wells Fargo
Trinity Capital initiated with an Overweight at Wells Fargo
EARS Auris Medical
/

+

HOME At Home Group
$36.99 /

+ (+0.00%)

05/10/21 Monness Crespi
At Home Group downgraded to Neutral from Buy at Monness Crespi
05/07/21
Fly Intel: Top five analyst downgrades
05/07/21 Craig-Hallum
At Home Group downgraded to Hold from Buy at Craig-Hallum
05/07/21 Craig-Hallum
At Home Group downgraded to Hold from Buy at Craig-Hallum
THCB Tuscan Holdings Corp.
$9.99 /

-0.21 (-2.06%)

HOME At Home Group
$36.99 /

+ (+0.00%)

EARS Auris Medical
/

+

  • 06
    Nov
LCID Lucid Group
/

+

HOME At Home Group
$36.99 /

+ (+0.00%)

EARS Auris Medical
/

+

CCIV Churchill Capital Corp IV
$24.22 /

+1.27 (+5.53%)

THCB Tuscan Holdings Corp.
$9.99 /

-0.21 (-2.06%)

LCID Lucid Group
/

+

HOME At Home Group
$36.99 /

+ (+0.00%)

EARS Auris Medical
/

+

CCIV Churchill Capital Corp IV
$24.22 /

+1.27 (+5.53%)

THCB Tuscan Holdings Corp.
$9.99 /

-0.21 (-2.06%)

HOME At Home Group
$36.99 /

+ (+0.00%)

EARS Auris Medical
/

+

CCIV Churchill Capital Corp IV
$24.22 /

+1.27 (+5.53%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.